On this page
Cerebral creatine deficiency (GAMT)
This rare inherited disorder occurs when the body cannot produce enough creatine, a vital molecule for energy in the brain and muscles. It typically leads to developmental delay, intellectual disability, and movement problems, often becoming apparent in early childhood.
Available at Jeen Health
Clinical tests that include this
Overview
Cerebral creatine deficiency due to GAMT (guanidinoacetate N-methyltransferase) is a rare inherited metabolic disorder that affects the body's ability to produce creatine [PMID:33678082]. Creatine is a crucial molecule that helps supply energy to cells, particularly in the brain and muscles. When the GAMT enzyme is not working correctly, toxic by-products can build up, and creatine levels in the brain become very low. This lack of creatine disrupts normal brain function and development, leading to various neurological symptoms. The condition is often diagnosed in early childhood, after symptoms begin to appear.
Symptoms & clinical features
Individuals with cerebral creatine deficiency due to GAMT typically experience a range of symptoms that can vary in severity. Common features include developmental delay, meaning children reach developmental milestones later than expected. This can affect cognitive skills and speech development, leading to intellectual disability and difficulties with communication [PMID:17918378]. Many individuals also have movement problems, such as muscle weakness (hypotonia), spasticity (stiff muscles), and ataxia (problems with coordination and balance). Epilepsy, characterised by recurrent seizures, is also a frequent symptom. Some affected individuals may exhibit autistic-like behaviours or experience gastrointestinal issues [PMID:33678082].
Video: Genetics 101
Affected organs
The primary organ affected by cerebral creatine deficiency due to GAMT is the brain. Creatine is essential for healthy brain energy metabolism, and its deficiency significantly impacts brain development and function. Low creatine levels in the brain lead to the neurological symptoms observed. While the brain is most prominently affected, creatine also plays a role in muscle energy, though muscle symptoms are typically less severe than neurological ones.
Risks & severity
Cerebral creatine deficiency due to GAMT is considered a severe condition, often leading to significant intellectual disability and lasting neurological impairments if not managed. The severity of symptoms can vary between individuals, even within the same family. Symptoms typically manifest in infancy or early childhood. If the condition is detected early and treatment is initiated, outcomes can sometimes be improved, but the optimal timing for intervention is crucial. Without treatment, the condition generally progresses, leading to severe developmental delays and neurological complications.
Genetic causes
Cerebral creatine deficiency is caused by pathogenic variants in the GAMT gene. The GAMT gene provides instructions for making an enzyme called guanidinoacetate N-methyltransferase. This enzyme is vital for the final step in the body's natural production of creatine. The GAMT protein converts guanidinoacetate (GAA) into creatine. When there are pathogenic changes in the GAMT gene, the enzyme either doesn't work correctly or is not produced efficiently [PMID:17918378]. This leads to a build-up of GAA, which can be toxic, and a severe shortage of creatine in the brain, impairing its energy supply.
- GAMT guanidinoacetate N-methyltransferaseThe GAMT gene provides instructions for an enzyme essential for the body's synthesis of creatine, a compound vital for energy storage and utilisation in muscles and the nervous system.
Inheritance pattern
Cerebral creatine deficiency due to GAMT has an autosomal recessive inheritance pattern. This means that an individual must inherit two copies of a pathogenic GAMT gene variant - one from each parent - to develop the condition. If a person inherits only one copy of the pathogenic variant, they are considered a carrier and typically do not show symptoms. When both parents are carriers, there is a 1 in 4 (25%) chance with each pregnancy that their child will inherit two copies of the variant and develop the condition, a 2 in 4 (50%) chance that their child will be a carrier, and a 1 in 4 (25%) chance that their child will inherit two unaffected gene copies and not be a carrier.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosing cerebral creatine deficiency typically begins with clinical suspicion based on a child's developmental delays, seizures, and movement problems. Initial screening can involve blood or urine tests to measure levels of guanidinoacetate (GAA) and creatine. High levels of GAA and low levels of creatine in these samples can indicate the condition. The diagnosis is confirmed through genetic testing, which involves analysing the GAMT gene for pathogenic variants. In the UK, genetic testing for this condition is part of the NHS Genomic Medicine Service, often initiated following referral to a clinical genetics service or specialist paediatrician. Relevant R-codes for genetic testing may apply.
Management & lifestyle
Management for cerebral creatine deficiency due to GAMT generally involves a multidisciplinary approach focused on reducing toxic substances and supplementing creatine. This typically includes dietary modifications to restrict arginine and glycine, which are precursors to guanidinoacetate, and supplementation with oral creatine monohydrate to try and replenish brain creatine levels [PMID:33678082]. In some cases, a medication called ornithine may also be used to help reduce GAA levels. Early diagnosis and prompt initiation of treatment are thought to offer the best chance for improving neurological outcomes, though responses can vary. Ongoing care is managed by a team of specialists, including metabolic consultants, neurologists, and dietitians within the NHS.
UK care pathway
In the UK, individuals suspected of having a genetic condition like cerebral creatine deficiency due to GAMT would typically be referred by their GP or a specialist paediatrician to an NHS clinical genetics service. This service can coordinate diagnostic genetic testing, which is performed under the NHS Genomic Medicine Service (GMS) pathways, often using specific R-codes. Following diagnosis, genetic counsellors are available to provide support, information, and discuss the implications of the condition for the individual and their wider family. Ongoing care and management are integrated within the NHS, often involving metabolic specialists and other paediatric teams.
Frequently asked questions
What is creatine and why is it important for the brain?
Creatine is a natural compound that plays a vital role in providing energy to cells, especially in organs that use a lot of energy, like the brain and muscles. It acts like an energy reserve, helping cells function efficiently. Without enough creatine, brain cells struggle to get the energy they need, leading to developmental and neurological problems.
Is cerebral creatine deficiency due to GAMT a common condition?
No, cerebral creatine deficiency due to GAMT is considered a rare genetic condition. The exact prevalence is not well established, but only a small number of affected individuals have been identified worldwide.
Can carriers of GAMT variants develop symptoms?
No, individuals who are carriers for a GAMT variant (meaning they have one unaffected copy and one pathogenic copy of the gene) typically do not develop symptoms of cerebral creatine deficiency. They usually have enough functional GAMT enzyme from their unaffected gene copy to produce sufficient creatine.
What kind of treatments are available for this condition?
Treatment for cerebral creatine deficiency due to GAMT generally involves a specific diet to limit substances that contribute to GAA buildup, along with taking oral creatine supplements. Sometimes, ornithine supplementation is also used. The goal is to reduce toxic by-products and increase creatine levels in the brain, and these treatments are usually managed by specialist NHS teams.
Will my GP know about cerebral creatine deficiency (GAMT)?
Given its rarity, your GP may not have direct experience with cerebral creatine deficiency due to GAMT. However, they are typically the first point of contact for referring patients to specialist services, such as paediatricians or clinical geneticists within the NHS, who are experts in diagnosing and managing such conditions.